BIOTON S.A.

Headquartered in Warsaw, Poland, a Warsaw Stock Exchange listed company, Bioton S.A. is among the first four companies worldwide being able to produce recombinant human insulin. This product is already registered on the most attractive markets.

Bioton is able to pursue its strategic objectives of protecting Patients’ health and improving the quality of their lives by participating in research and development projects and promoting the expansion of its product portfolio to deliver to the market most innovative pharmaceutical products.. Bioton Group developed its global position by targeting the most attractive insulin markets – among them Poland, Russia, Ukraine, China, India and other Asia Pacific countries. Bioton’s aim is to build strong, international operations focused on sales of insulin and other biotech products, development of new clinically important drugs and strategic alliances with world’s leading pharmaceutical companies.